The association of dehydroepiandrosterone, obesity, waist-hip ratio and insulin resistance with fatty liver in postmenopausal women - A hyperinsulinemic euglycemic insulin clamp study

Hepato-Gastroenterology

Volumn 50, Issue 51, 2003, Pages 771-774

  Saruç, Murat ^a,b   Yuceyar H ^a   Ayhan, S ^a   Turkel N ^a   Tuzcuoglu, I ^a   Can, M ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Dehydroepiandrosterone; Diabetes; Fatty liver; Insulin resistance; Obesity

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; PRASTERONE; PRASTERONE SULFATE; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY FAT; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; INSULIN RESISTANCE; LIVER BIOPSY; LIVER DISEASE; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; WAIST HIP RATIO;

BLOOD GLUCOSE; BODY COMPOSITION; BODY CONSTITUTION; BODY MASS INDEX; CHOLESTEROL; CLIMACTERIC; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FATTY LIVER; FEMALE; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; LIVER; MIDDLE AGED; OBESITY; TRIGLYCERIDES;

EID: 0038238866     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ebeling P, Koivisto VA: Physiological importance of dehydroepiandrosteron. Lancet Vol 343; 1994:1479-1481.
2. Orentreich N, Brind JL, Rizer RL, Vogelman JH: Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59:551-555.
3. vy/ a mice by dehydroepiandrosterone. Lipids 1977; 12:409-413.
4. Berdainer CD, Parente Jr JA, McIntosh MK: Is dehydroepiandrosterone an antiobesity agent? FASEB J 1993; 7:414-419.
5. Coleman DL, Leiter EH, Applezwig N: Therapeutic effects of dehydroepiandrosterone metabolites in diabetes mutant mice (C57BL/Ksj-db/db). Endocrinology 1984; 115:239-243.
6. Coleman DL, Schwizer RW, Leiter EH: Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and in aged normal mice. Diabetes 1984; 33:26-32.
7. Goto H, Yamashita S, Makita T: Preventive effect of dehydroepiandrosterone acetate on fatty liver induced by orotic acid in male rats. Exp Anim 1998; 47(4):257-260.
8. Luyckx FH, Lefebvre PJ, Scheen AJ: Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000; 26:98-106.
9. Petrides AS, Strohmeyer G: Insulin resistance in liver diseases. Z Gastroenterol 1986; 24:403-415.
10. Saruc M, Goksel G, Yorulmaz I, Goktan C, Yuceyar H: Factors other than alcohol causing fatty liver. Klinik Bilimler ve Doktor 2000; 6:427-430.
11. Freidenberg GR, Suter SL, Henry RR, Reichart D, Olefsky JM: In vivo stimulation of the insulin receptor kinase in human skeletal muscle. Correlation with insulin stimulated glucose disposal during euglycemic clamp studies. J Clin Invest 1991; 87:2222-2229.
12. Barrett-Conor E, Ferrara A: Dehydroepiandrosterone, dahydroepiandrosteron sulfate, obesity, waist-hip ratio, and non-insulin dependent diabetes in postmenopausal women: The Rancho Bernardo Study. J Clin Endocrinol Metabol 1996; 81:59-64.
13. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120:1281-1285.
14. Drucker WD, Blumberg JM, Gandy HM, David RR, Verde AL: Biologic activity of dehydroepiandrosterone sulfate in man. J Clin Endocrinol Metab 1972; 35:48-54.
15. Poortman J, Prenen JAC, Schwarz F, Thijsen JHH: Interaction of Δ5-androstene-3β, 17β-diol with estradiol and dihydrotesterone receptors in human myometrial and mammary cancer tissue. J Clin Endocrinol Metab 1975; 40:373-379.
16. Seymour-Munn K, Adams J: Estorogenic effects of 5-androstene-3β, 17β-diol at physiological concentrations and its possible implications in the etiology of breast cancer. Endocrinology 1982; 112:486-491.
17. Bird CE, Murphy J, Boroomand K, et al: Dehydroepiandrosterone: kinetics of metabolism in normal men and women. J Clin Endocrinol Metab 1978; 47:818-822.
18. Mortola JF, Yen SS: The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990; 71:696-704.
19. Fried SK, russel CD, Grauso NL, Brolin RE: Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissue of obese women and men. J Clin Invest 1993; 92:2191-2198.
20. Marin P, Darin N, Amemiya T, et al: Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 1992; 41:882-886.
21. Williams DP, Boyden TW, Pamenter RW, et al: Relationship of body fat percentage and fat distribution with dehydroepiandrosterone sulfate in premenopausal females. J Clin Endocrinol 1993; 77:80-85.
22. Usiskin KS, Butterworth S, Clore JN, et al: Lack of effect of dehydroepiandrosterone in obese men. Int J Obesity 1990; 14:457-463.
23. Khaw KT, Barret-Connor E: Fasting plasma glucose levels and endogenous androgens in non-diabetic postmenopausal women. Clin Sci 1991; 80:199-203.
24. Bolinder J, Kager L, Östman J, Arner P: Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes 1983; 32:117-123.
25. Björntorp P: Metabolic implications of body fat distribution. Diabetes Care 1991; 14:1132-1143.